data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Evofem Biosciences
(NASDAQ:EVFM)
$1.13
0.1494[15.24%]
At close: Jun 30
$1.16
0.0300[2.65%]
After Hours: 7:59PM EDT
Day High/Low0.81 - 1.2
52 Week High/Low0.11 - 1.51
Open / Close0.95 / 1.13
Float / Outstanding35.2M / 35.4M
Vol / Avg.119.1M / 20.3M
Mkt Cap40M
P/E-
50d Avg. Price0.51
Div / Yield-
Payout Ratio-
EPS-2.88
Total Float35.2M

Evofem Biosciences (NASDAQ:EVFM), Quotes and News Summary

Evofem Biosciences (NASDAQ: EVFM)

Day High/Low0.81 - 1.2
52 Week High/Low0.11 - 1.51
Open / Close0.95 / 1.13
Float / Outstanding35.2M / 35.4M
Vol / Avg.119.1M / 20.3M
Mkt Cap40M
P/E-
50d Avg. Price0.51
Div / Yield-
Payout Ratio-
EPS-2.88
Total Float35.2M
Benzinga - 8 hours ago
Benzinga - 13 hours ago
Benzinga - 2 days ago
Benzinga - 2 days ago
Benzinga - 2 days ago
Benzinga - 2 days ago
Benzinga - 3 days ago
Benzinga - 3 days ago
Benzinga - 3 days ago
Benzinga - Jun 16, 2022, 8:47AM
load more
Sector: Health Care.Industry: Pharmaceuticals
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The company's product, Phexxi (lactic acid, citric acid and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The company is also evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-10
REV
Q1 2022Est.ActualSurprise
EPS-3.000-2.880 0.1200
REV4.150M4.251M101.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Evofem Biosciences Questions & Answers

Q
How do I buy Evofem Biosciences (EVFM) stock?
A

You can purchase shares of Evofem Biosciences (NASDAQ: EVFM) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Evofem Biosciences's (EVFM) competitors?
Q
What is the target price for Evofem Biosciences (EVFM) stock?
A

The latest price target for Evofem Biosciences (NASDAQ: EVFM) was reported by Laidlaw & Co. on Thursday, June 2, 2022. The analyst firm set a price target for 3.50 expecting EVFM to rise to within 12 months (a possible 209.73% upside). 10 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Evofem Biosciences (EVFM)?
A

The stock price for Evofem Biosciences (NASDAQ: EVFM) is $1.13 last updated June 30, 2022, 8:00 PM UTC.

Q
Does Evofem Biosciences (EVFM) pay a dividend?
A

There are no upcoming dividends for Evofem Biosciences.

Q
When is Evofem Biosciences (NASDAQ:EVFM) reporting earnings?
A

Evofem Biosciences’s Q2 earnings are confirmed for Wednesday, August 10, 2022.

Q
Is Evofem Biosciences (EVFM) going to split?
A

There is no upcoming split for Evofem Biosciences.

Q
What sector and industry does Evofem Biosciences (EVFM) operate in?
A

Evofem Biosciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.